JP2005507637A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507637A5 JP2005507637A5 JP2002568744A JP2002568744A JP2005507637A5 JP 2005507637 A5 JP2005507637 A5 JP 2005507637A5 JP 2002568744 A JP2002568744 A JP 2002568744A JP 2002568744 A JP2002568744 A JP 2002568744A JP 2005507637 A5 JP2005507637 A5 JP 2005507637A5
- Authority
- JP
- Japan
- Prior art keywords
- propeptide
- modified
- gdf
- pharmaceutical composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 73
- 108010056852 Myostatin Proteins 0.000 claims 73
- 239000008194 pharmaceutical composition Substances 0.000 claims 54
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 53
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 claims 53
- 150000007523 nucleic acids Chemical class 0.000 claims 39
- 108020004707 nucleic acids Proteins 0.000 claims 36
- 102000039446 nucleic acids Human genes 0.000 claims 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 21
- 208000035475 disorder Diseases 0.000 claims 21
- 230000000087 stabilizing effect Effects 0.000 claims 21
- 102000009027 Albumins Human genes 0.000 claims 14
- 108010088751 Albumins Proteins 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000002299 complementary DNA Substances 0.000 claims 12
- 230000035772 mutation Effects 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 12
- 125000003729 nucleotide group Chemical group 0.000 claims 12
- 230000006337 proteolytic cleavage Effects 0.000 claims 12
- 238000000338 in vitro Methods 0.000 claims 8
- 238000001727 in vivo Methods 0.000 claims 8
- 125000000837 carbohydrate group Chemical group 0.000 claims 7
- 230000013595 glycosylation Effects 0.000 claims 7
- 238000006206 glycosylation reaction Methods 0.000 claims 7
- 235000018102 proteins Nutrition 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 108091034117 Oligonucleotide Proteins 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- 208000021642 Muscular disease Diseases 0.000 claims 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 5
- 208000030159 metabolic disease Diseases 0.000 claims 5
- 201000006938 muscular dystrophy Diseases 0.000 claims 5
- 208000018360 neuromuscular disease Diseases 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 229920000642 polymer Polymers 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 206010002329 Aneurysm Diseases 0.000 claims 3
- 206010006895 Cachexia Diseases 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 208000026062 Tissue disease Diseases 0.000 claims 3
- 210000000577 adipose tissue Anatomy 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 230000003412 degenerative effect Effects 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000003387 muscular Effects 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 238000000746 purification Methods 0.000 claims 3
- 208000001076 sarcopenia Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 201000009623 Myopathy Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26750901P | 2001-02-08 | 2001-02-08 | |
| PCT/US2002/003467 WO2002068650A2 (en) | 2001-02-08 | 2002-02-08 | Modified and stabilized gdf propeptides and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005209321A Division JP2006001938A (ja) | 2001-02-08 | 2005-07-19 | 改変され安定化されたｇｄｆプロペプチドおよびその使用 |
| JP2008298812A Division JP5013618B2 (ja) | 2001-02-08 | 2008-11-21 | 改変され安定化されたｇｄｆプロペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005507637A JP2005507637A (ja) | 2005-03-24 |
| JP2005507637A5 true JP2005507637A5 (enExample) | 2006-01-05 |
| JP4280071B2 JP4280071B2 (ja) | 2009-06-17 |
Family
ID=23019083
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002568744A Expired - Fee Related JP4280071B2 (ja) | 2001-02-08 | 2002-02-08 | 改変され安定化されたｇｄｆプロペプチドおよびその使用 |
| JP2005209321A Withdrawn JP2006001938A (ja) | 2001-02-08 | 2005-07-19 | 改変され安定化されたｇｄｆプロペプチドおよびその使用 |
| JP2008298812A Expired - Fee Related JP5013618B2 (ja) | 2001-02-08 | 2008-11-21 | 改変され安定化されたｇｄｆプロペプチドおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005209321A Withdrawn JP2006001938A (ja) | 2001-02-08 | 2005-07-19 | 改変され安定化されたｇｄｆプロペプチドおよびその使用 |
| JP2008298812A Expired - Fee Related JP5013618B2 (ja) | 2001-02-08 | 2008-11-21 | 改変され安定化されたｇｄｆプロペプチドおよびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US7202210B2 (enExample) |
| EP (1) | EP1397492B1 (enExample) |
| JP (3) | JP4280071B2 (enExample) |
| AR (1) | AR032567A1 (enExample) |
| AT (1) | ATE357519T1 (enExample) |
| AU (1) | AU2002243852B2 (enExample) |
| BR (1) | BR0207110A (enExample) |
| CA (2) | CA2674673A1 (enExample) |
| CL (1) | CL2009000648A1 (enExample) |
| CY (1) | CY1106629T1 (enExample) |
| DE (1) | DE60219006T2 (enExample) |
| DK (1) | DK1397492T3 (enExample) |
| ES (1) | ES2284828T3 (enExample) |
| MX (1) | MXPA03007063A (enExample) |
| NO (1) | NO333427B1 (enExample) |
| NZ (2) | NZ550297A (enExample) |
| PL (2) | PL212078B1 (enExample) |
| PT (1) | PT1397492E (enExample) |
| SG (2) | SG165982A1 (enExample) |
| TW (2) | TWI329129B (enExample) |
| WO (1) | WO2002068650A2 (enExample) |
| ZA (2) | ZA200508954B (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| PL375045A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Gasp1: a follistatin domain containing protein |
| PL374966A1 (en) * | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| JP2006507356A (ja) * | 2002-09-16 | 2006-03-02 | ワイエス | ミオスタチンのメタロプロテアーゼ活性化およびミオスタチン活性の調節方法 |
| AR047392A1 (es) * | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| AU2003225410A1 (en) | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| WO2004108157A2 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
| ES2561048T3 (es) * | 2004-07-23 | 2016-02-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| US20060034831A1 (en) * | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| US8088508B2 (en) | 2005-01-31 | 2012-01-03 | Panasonic Corporation | Thermal battery |
| US20060216279A1 (en) * | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| BRPI0609439A2 (pt) * | 2005-03-23 | 2010-04-06 | Wyeth Corp | detecção de uma resposta imunológica a agentes moduladores de gdf-8 |
| JP2008537488A (ja) * | 2005-03-23 | 2008-09-18 | ワイス | Ｇｄｆ−８モジュレート物質の検出 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| ME00380B (me) * | 2005-11-23 | 2011-10-10 | Acceleron Pharma Inc | Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti |
| US20070190056A1 (en) * | 2006-02-07 | 2007-08-16 | Ravi Kambadur | Muscle regeneration compositions and uses therefor |
| JP5564249B2 (ja) * | 2006-06-23 | 2014-07-30 | アレシア・バイオセラピューティクス・インコーポレーテッド | 癌に関与するポリヌクレオチド配列およびポリペプチド配列 |
| JP6047270B2 (ja) | 2006-08-11 | 2016-12-21 | バイオマリン テクノロジーズ ベー．フェー． | Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段 |
| US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CN104524548A (zh) * | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
| US9526759B2 (en) * | 2007-02-01 | 2016-12-27 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TW201940502A (zh) * | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| KR101672156B1 (ko) * | 2007-02-09 | 2016-11-02 | 악셀레론 파마 인코포레이티드 | 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
| JP5706157B2 (ja) * | 2007-07-12 | 2015-04-22 | プロセンサ テクノロジーズ ビー．ブイ．Ｐｒｏｓｅｎｓａ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． | 化合物を種々の選択臓器又は組織に標的化するための分子 |
| WO2009008725A2 (en) * | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| PE20090510A1 (es) | 2007-08-03 | 2009-05-22 | Summit Corp Plc | Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| CN107412734A (zh) | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| DK2203173T3 (en) | 2007-10-26 | 2016-02-29 | Academisch Ziekenhuis Leiden | Materials and methods for prevention of muscle diseases |
| EP2249874A1 (en) * | 2008-02-08 | 2010-11-17 | ProSensa Holding BV | Methods and means for treating dna repeat instability associated genetic disorders |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| CA2723987C (en) | 2008-05-14 | 2019-06-11 | Agriculture Victoria Services Pty Ltd | Use of angiogenin or angiogenin agonists for treating diseases and disorders |
| KR101871510B1 (ko) * | 2008-06-26 | 2018-06-26 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| LT3750552T (lt) * | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
| WO2010060186A1 (en) | 2008-11-03 | 2010-06-03 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
| CA2749544A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| ES2593836T3 (es) | 2009-04-24 | 2016-12-13 | Biomarin Technologies B.V. | Oligonucleótido que comprende una inosina para tratar la DMD |
| MX385318B (es) | 2009-06-08 | 2025-03-18 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
| JP2012529294A (ja) | 2009-06-12 | 2012-11-22 | アクセルロン ファーマ， インコーポレイテッド | 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質 |
| ES2613523T3 (es) * | 2009-09-09 | 2017-05-24 | Acceleron Pharma, Inc. | Antagonistas de ActRIIb y dosificación y usos de los mismos |
| US20110129469A1 (en) * | 2009-11-03 | 2011-06-02 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| TW201120210A (en) | 2009-11-05 | 2011-06-16 | Hoffmann La Roche | Glycosylated repeat-motif-molecule conjugates |
| EP2501400B1 (en) | 2009-11-17 | 2017-11-01 | Acceleron Pharma, Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| WO2011078672A1 (en) | 2009-12-24 | 2011-06-30 | Prosensa Technologies B.V. | Molecule for treating an inflammatory disorder |
| WO2012023085A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
| WO2012064771A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
| JP6294221B2 (ja) | 2011-03-31 | 2018-03-14 | アー・デー・ツェー・セラピューティクス・エス・アー | 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント |
| KR20140077977A (ko) | 2011-10-21 | 2014-06-24 | 화이자 인코포레이티드 | 철을 첨가하여 세포 배양을 개선하는 방법 |
| TR201908872T4 (tr) | 2012-01-09 | 2019-07-22 | Adc Therapeutics Sa | Üçlü negatif meme kanserini tedavi etmek için ajanlar. |
| ES2907250T3 (es) | 2012-01-27 | 2022-04-22 | Biomarin Tech Bv | Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de la distrofia muscular de Duchenne y de Becker |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| AU2013204740C1 (en) | 2012-05-10 | 2015-10-01 | Agriculture Victoria Services Pty Ltd | Methods of treating cancer using angiogenin or an angiogenin agonist |
| WO2014000042A1 (en) * | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS |
| EP2880053B8 (en) | 2012-08-01 | 2020-04-15 | Ikaika Therapeutics, LLC | Mitigating tissue damage and fibrosis via anti-ltbp4 antibody |
| CN104822826B (zh) | 2012-10-15 | 2019-04-30 | 百时美施贵宝公司 | 用于蛋白产生的哺乳动物细胞培养过程 |
| JP6401172B2 (ja) | 2012-10-24 | 2018-10-10 | セルジーン コーポレイション | 貧血の治療方法 |
| CA2889209C (en) * | 2012-10-24 | 2023-08-22 | Celgene Corporation | Biomarker for use in treating anemia |
| RU2018145985A (ru) | 2012-11-02 | 2019-02-18 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| WO2014119753A1 (ja) * | 2013-01-31 | 2014-08-07 | 学校法人 東京薬科大学 | マイオスタチン阻害ペプチド |
| ES2924479T3 (es) | 2013-04-08 | 2022-10-07 | Harvard College | Composiciones para rejuvenecer las células madre del músculo esquelético |
| EP3881859B1 (en) * | 2013-06-11 | 2024-03-06 | President and Fellows of Harvard College | Compositions for increasing neurogenesis and angiogenesis |
| TN2016000035A1 (en) * | 2013-07-31 | 2017-07-05 | Amgen Inc | Growth differentiation factor 15 (gdf-15) constructs |
| CN104725513A (zh) * | 2013-12-20 | 2015-06-24 | 中国科学院上海生命科学研究院 | 融合蛋白及其在治疗多发性硬化中的用途 |
| TN2016000553A1 (en) | 2014-06-13 | 2018-04-04 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| UA123432C2 (uk) | 2014-07-30 | 2021-04-07 | Нджм Біофармасьютікалз, Інк. | Димер та спосіб його застосування для лікування метаболічних розладів |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| MD20170035A2 (ro) | 2014-10-31 | 2017-09-30 | Ngm Biopharmaceuticals Inc | Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice |
| DK3227675T3 (da) | 2014-12-03 | 2023-05-30 | Celgene Corp | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom |
| CN116059320A (zh) | 2016-01-06 | 2023-05-05 | 哈佛学院校长同事会 | 使用gdf11的治疗防止体重增加、提高葡萄糖耐量并减轻脂肪肝 |
| CN117986363A (zh) | 2016-03-31 | 2024-05-07 | 恩格姆生物制药公司 | 结合蛋白及其使用方法 |
| CA3124415A1 (en) | 2018-12-21 | 2020-06-25 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| DE3382562D1 (de) | 1982-09-24 | 1992-06-25 | Us Health | Wiederherstellung von gewebe bei tieren. |
| US4588684A (en) | 1983-04-26 | 1986-05-13 | Chiron Corporation | a-Factor and its processing signals |
| NZ210699A (en) | 1984-01-04 | 1989-06-28 | Int Genetic Eng | Isolation of an osteogenic protein of the p3 immunologically related family |
| ZA848495B (en) | 1984-01-31 | 1985-09-25 | Idaho Res Found | Production of polypeptides in insect cells |
| CA1341617C (en) | 1984-06-08 | 2011-06-28 | Henry George Burger | Inhibin isolated from ovarian follicular fluid |
| DE3588199T2 (de) | 1984-07-06 | 1999-04-08 | Novartis Ag, Basel | Lymphokin-Herstellung und -Reinigung |
| DE3588058T3 (de) | 1984-07-16 | 2005-04-07 | Celtrix Pharmaceuticals, Inc., Palo Alto | Knorpel-induzierende Polypeptid-Faktoren aus Knochen |
| US4740587A (en) | 1985-07-18 | 1988-04-26 | The Salk Institute For Biological Studies | Inhibin and method of purifying same |
| US5215893A (en) | 1985-10-03 | 1993-06-01 | Genentech, Inc. | Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
| US4798885A (en) | 1986-02-07 | 1989-01-17 | Genentech, Inc. | Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain |
| NZ231899A (en) | 1985-10-03 | 1991-07-26 | Genentech Inc | Human or porcine inhibin peptide compositions and dna encoding them |
| US5089396A (en) | 1985-10-03 | 1992-02-18 | Genentech, Inc. | Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
| US4737578A (en) | 1986-02-10 | 1988-04-12 | The Salk Institute For Biological Studies | Human inhibin |
| US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| ZA874681B (en) | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
| US5106748A (en) | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5187076A (en) | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
| US5041538A (en) | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
| AU645244B2 (en) | 1988-04-08 | 1994-01-13 | Genetics Institute, Llc | Bone and cartilage inductive compositions |
| US5071834A (en) | 1988-09-16 | 1991-12-10 | Genentech, Inc. | Purified activin B composition |
| CA2030518C (en) | 1989-03-28 | 2000-03-21 | Elizabeth A. Wang | Osteoinductive compositions |
| EP0394827A1 (en) * | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| CA2020729A1 (en) | 1989-07-19 | 1991-01-20 | Michael C. Kiefer | Bone morphogenetic protein |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5116944A (en) * | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
| US5166190A (en) | 1990-01-08 | 1992-11-24 | Genentech, Inc. | Method for increasing fertility in males |
| JPH06500991A (ja) | 1990-05-16 | 1994-01-27 | ジェネティックス・インスティテュート・インコーポレイテッド | 骨および軟骨誘導蛋白質 |
| WO1992005199A1 (en) | 1990-09-26 | 1992-04-02 | Genetics Institute, Inc. | Bmp-5 derivatives |
| CA2071912C (en) | 1990-11-30 | 2002-10-15 | Hanne Bentz | Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair |
| US5208219A (en) | 1991-02-14 | 1993-05-04 | Celtrix Pharmaceuticals Inc. | Method for inducing bone growth |
| US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| AU662155B2 (en) | 1991-05-10 | 1995-08-24 | Celtrix Pharmaceuticals, Inc. | Targeted delivery of bone growth factors |
| DK0592562T3 (da) | 1991-06-25 | 1999-08-30 | Genetics Inst | BMP-9-præparater |
| KR100238712B1 (ko) * | 1991-06-27 | 2000-01-15 | 스티븐 비. 데이비스 | 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도 |
| US5171579A (en) | 1991-10-11 | 1992-12-15 | Genetics Institute, Inc. | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
| DE69233022T2 (de) | 1991-11-04 | 2004-02-12 | Genetics Institute, LLC, Cambridge | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
| DE69333040T3 (de) | 1992-07-31 | 2007-10-11 | Curis, Inc., Cambridge | Morphogen induzierte nerven wiederherstellung und wiedergutmachung. |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| US20030074680A1 (en) | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| ES2201076T3 (es) | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
| US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| US6673534B1 (en) | 1995-10-26 | 2004-01-06 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
| KR100227406B1 (ko) | 1993-05-12 | 1999-12-01 | 브루스 엠. 에이센 | Bmp-11 조성물 |
| CA2169191C (en) | 1993-08-26 | 2008-01-15 | Elizabeth A. Wang | Neural regeneration using human bone morphogenetic proteins |
| US7332575B2 (en) | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
| US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
| DK0776337T3 (da) | 1994-07-08 | 2005-12-12 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-11 |
| US5466190A (en) * | 1994-07-25 | 1995-11-14 | Deere & Company | Precleaner for a cleaning shoe |
| US5545616A (en) | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
| JPH10262688A (ja) * | 1994-11-30 | 1998-10-06 | Univ Rockefeller | 体重のモジュレーター、対応する核酸およびタンパク質、ならびにそれらの診断および治療用途 |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| JP4847634B2 (ja) | 1996-03-22 | 2011-12-28 | ストライカー・コーポレーション | 中枢神経系の虚血または外傷の機能的回復を増大させる方法 |
| US6696557B1 (en) * | 1996-04-19 | 2004-02-24 | Genentech, Inc. | AL-2 neurotrophic factor nucleic acid |
| PE99498A1 (es) * | 1996-07-26 | 1999-01-21 | Novartis Ag | Polipeptidos de fusion |
| WO1998033887A1 (en) | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| WO1999002667A1 (en) * | 1997-07-14 | 1999-01-21 | University Of Liege | Mutations in the myostation gene cause double-muscling in mammals |
| US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| GB2345397B (en) * | 1997-08-19 | 2001-10-31 | Citizen Watch Co Ltd | Piezoelectric vibrator |
| AU8921698A (en) | 1997-08-29 | 1999-03-16 | Human Genome Sciences, Inc. | Follistatin-3 |
| AU1276399A (en) | 1997-11-07 | 1999-05-31 | Genetics Institute Inc. | Neuronal uses of bmp-11 |
| AU1390999A (en) | 1997-11-10 | 1999-05-31 | Johns Hopkins University School Of Medicine, The | Methods for detection of mutations in myostatin variants |
| AU2586199A (en) | 1998-02-05 | 1999-08-23 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| AU765214B2 (en) | 1998-05-06 | 2003-09-11 | Metamorphix International, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
| CA2339968A1 (en) * | 1998-08-20 | 2000-03-02 | Regeneron Pharmaceuticals, Inc. | Dcr5, a bmp-binding protein, and applications thereof |
| EP1147413B1 (en) * | 1999-01-21 | 2006-04-05 | Metamorphix, Inc. | Growth differentiation factor inhibitors and uses therefor |
| AU782493B2 (en) * | 1999-06-01 | 2005-08-04 | Curis, Inc. | Polymer conjugates of hedgehog proteins and uses |
| KR100750695B1 (ko) | 1999-07-20 | 2007-08-22 | 파멕사 에이/에스 | Ｇｄｆ-8 활성을 하향-조절하는 방법 |
| WO2001064888A2 (en) | 2000-02-29 | 2001-09-07 | Zymogenetics, Inc. | Kunitz domain polypeptide zkun8 |
| US7037501B2 (en) | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| PL350983A1 (en) * | 2001-11-30 | 2003-06-02 | Advanced Digital Broadcast Ltd | Method of scanning a high-frequency signal band and apparatus therefor |
| PL374966A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| PL375045A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Gasp1: a follistatin domain containing protein |
| JP2006507356A (ja) | 2002-09-16 | 2006-03-02 | ワイエス | ミオスタチンのメタロプロテアーゼ活性化およびミオスタチン活性の調節方法 |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| KR20130036378A (ko) | 2002-12-20 | 2013-04-11 | 암겐 인코포레이티드 | 미오스타틴을 저해하는 결합제 |
| WO2004108157A2 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
| JP2008537488A (ja) | 2005-03-23 | 2008-09-18 | ワイス | Ｇｄｆ−８モジュレート物質の検出 |
| BRPI0609439A2 (pt) | 2005-03-23 | 2010-04-06 | Wyeth Corp | detecção de uma resposta imunológica a agentes moduladores de gdf-8 |
-
2002
- 2002-02-07 TW TW091102268A patent/TWI329129B/zh not_active IP Right Cessation
- 2002-02-07 TW TW094108366A patent/TW200526779A/zh unknown
- 2002-02-08 BR BR0207110-0A patent/BR0207110A/pt not_active IP Right Cessation
- 2002-02-08 DK DK02709366T patent/DK1397492T3/da active
- 2002-02-08 SG SG200506783-0A patent/SG165982A1/en unknown
- 2002-02-08 SG SG2010040194A patent/SG187989A1/en unknown
- 2002-02-08 DE DE60219006T patent/DE60219006T2/de not_active Expired - Lifetime
- 2002-02-08 WO PCT/US2002/003467 patent/WO2002068650A2/en not_active Ceased
- 2002-02-08 PT PT02709366T patent/PT1397492E/pt unknown
- 2002-02-08 MX MXPA03007063A patent/MXPA03007063A/es active IP Right Grant
- 2002-02-08 AT AT02709366T patent/ATE357519T1/de active
- 2002-02-08 JP JP2002568744A patent/JP4280071B2/ja not_active Expired - Fee Related
- 2002-02-08 ZA ZA200508954A patent/ZA200508954B/en unknown
- 2002-02-08 NZ NZ550297A patent/NZ550297A/en not_active IP Right Cessation
- 2002-02-08 NZ NZ527286A patent/NZ527286A/en not_active IP Right Cessation
- 2002-02-08 AR ARP020100421A patent/AR032567A1/es not_active Application Discontinuation
- 2002-02-08 AU AU2002243852A patent/AU2002243852B2/en not_active Ceased
- 2002-02-08 US US10/071,499 patent/US7202210B2/en not_active Expired - Fee Related
- 2002-02-08 CA CA002674673A patent/CA2674673A1/en not_active Abandoned
- 2002-02-08 EP EP02709366A patent/EP1397492B1/en not_active Expired - Lifetime
- 2002-02-08 ES ES02709366T patent/ES2284828T3/es not_active Expired - Lifetime
- 2002-02-08 PL PL390369A patent/PL212078B1/pl unknown
- 2002-02-08 CA CA002437218A patent/CA2437218A1/en not_active Abandoned
- 2002-02-08 PL PL372888A patent/PL207202B1/pl unknown
-
2003
- 2003-08-04 NO NO20033456A patent/NO333427B1/no not_active IP Right Cessation
- 2003-08-06 ZA ZA200306064A patent/ZA200306064B/en unknown
-
2005
- 2005-07-19 JP JP2005209321A patent/JP2006001938A/ja not_active Withdrawn
-
2006
- 2006-12-21 US US11/614,702 patent/US7737116B2/en not_active Expired - Fee Related
- 2006-12-21 US US11/614,594 patent/US7560441B2/en not_active Expired - Fee Related
-
2007
- 2007-05-29 CY CY20071100719T patent/CY1106629T1/el unknown
-
2008
- 2008-11-21 JP JP2008298812A patent/JP5013618B2/ja not_active Expired - Fee Related
-
2009
- 2009-03-18 CL CL2009000648A patent/CL2009000648A1/es unknown
- 2009-05-04 US US12/434,758 patent/US8222384B2/en not_active Expired - Fee Related
-
2012
- 2012-06-14 US US13/523,391 patent/US8710025B2/en not_active Expired - Fee Related
-
2013
- 2013-09-19 US US14/032,079 patent/US20140228289A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005507637A5 (enExample) | ||
| JP2005534616A5 (enExample) | ||
| US20230312696A1 (en) | Compositions and Methods of Use for Treating Metabolic Disorders | |
| JP4988599B2 (ja) | Ｉｇｆ−１融合ポリペプチドおよびその治療的使用 | |
| CN103547590B (zh) | 高度可溶性瘦蛋白 | |
| JP4659068B2 (ja) | Ｏｂ融合タンパク質組成物および方法 | |
| EP2507267B1 (en) | Compositions and methods for increasing serum half-life of fc fusion proteins | |
| JP6038905B2 (ja) | オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途 | |
| JP6923115B2 (ja) | 高グリコシル化ヒト血液凝固第ｖｉｉｉ因子の融合タンパク質、その調製方法、および使用 | |
| JP2005531505A5 (enExample) | ||
| CN103957926B (zh) | 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽 | |
| JP7046903B2 (ja) | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 | |
| WO2002068650B1 (en) | Modified and stabilized gdf propeptides and uses thereof | |
| EA019203B1 (ru) | Коагонисты глюкагонового рецептора/glp-1-рецептора | |
| JP7702445B2 (ja) | 免疫調節融合タンパク質 | |
| JP2002527052A (ja) | 改善された生物活性と生体適合性のためのタンパク質の部位特異的二重ポリエチレングリコール化 | |
| MX2013010011A (es) | Agentes de unión biespecífica. | |
| JPH11505109A (ja) | Ｏｂ蛋白の生物学的活性ペプチドフラグメント | |
| JP2008502301A (ja) | ペプチドの抱合 | |
| JP2022118184A (ja) | コンジュゲートされたｃ１エステラーゼインヒビター及びその使用 | |
| JP2009510999A (ja) | キメラ治療剤 | |
| JP2002512199A5 (enExample) | ||
| CN116635050A (zh) | 对胰高血糖素、glp-1和gip受体全部具有活性的新型三重激动剂及其用途 | |
| CN106279430B (zh) | Exendin‑4类似物融合蛋白及其制备方法和用途 | |
| JP2005518183A5 (enExample) |